Not available outside of the UK & Ireland.
Application
GR 113808 has been used as a serotonin receptor 4 (5-HT4R) blocker to study its effects on the calcium (Ca2+) transients in rat ventricular cardiomyocytes. It has also been used as a 5-HT4R antagonist to study its effects on de novo enteric neurogenesis in post-embryonic zebrafish.
Biochem/physiol Actions
GR 113808 is a 5-HT4 serotonin receptor antagonist.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
Packaging
10, 50 mg in glass bottle
This product has met the following criteria to qualify for the following awards: